Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55777 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL12253189 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL6692098 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL12595172 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL11913572 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL9639261 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| Triethylene Glycol SCHEMBL55776 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL9639239 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL19000744 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT | |
| SCHEMBL14495475 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114025736-A | Topical scalp care compositions | 宝洁公司 | 2022-02-08 | — | — | CN | disclosed |
| US-9815790-B2 | Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-14 | — | — | US | disclosed |
| US-20170179362-A1 | THERMOELECTRIC CONVERSION ELEMENT, n-TYPE THERMOELECTRIC CONVERSION LAYER, AND COMPOSITION FOR FORMING n-TYPE THERMOELECTRIC CONVERSION LAYER | FUJIFILM CORPORATION (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170057922-A1 | CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
| US-5120459-A | Functional fluids | MONSANTO COMPANY (US) | 1992-06-09 | — | — | US | disclosed |
| US-5076949-A | Novel perfluorinated polyethers and process for their preparation | MONSANTO COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
| US-4996369-A | Perfluoroheptaglyme dimer; lubricants; heat exchangers; vacuum pump oils | MONSANTO COMPANY (US) | 1991-02-26 | — | — | US | disclosed |
| US-4871109-A | PERFLUOROHEPTAGLYME; NONTOXIC | MONSANTO COMPANY (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0332601-A1 | Novel perfluorinated polyethers and process for their preparation | Monsanto Company (US) | 1989-09-13 | — | — | EP | disclosed |
| EP-0326539-A1 | Vapor phase soldering using certain perfluorinated polyethers | Monsanto Company (US) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057922-A1 | CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, CNR2, OPRK1 | MEN1 2202/4885KMT2A 1959/4885TSHR 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.